This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877–90.
Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672–81.
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154–65.
Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman Disease. Haematologica. 2020;105:348–57.
Chen J, Zhao AL, Duan MH, Cai H, Gao XM, Liu T, et al. Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis. Leukemia. 2022;36:573–6.
Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022;139:2601–21.
Saboo SS, Jagannathan JP, Krajewski KM, O’Regan K, Hornick JL, Fisher DC, et al. Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery. J Clin Oncol. 2011;29:e772–e775.
Chen E, Pavlidakey P, Sami N. Rosai-Dorfman disease successfully treated with thalidomide. Jaad Case Rep. 2016;2:369–72.
Rubinstein M, Assal A, Scherba M, Elman J, White R, Verma A, et al. Lenalidomide in the treatment of Rosai Dorfman disease–a first in use report. Am J Hematol. 2016;91:E1.
Abeykoon JP, Rech KL, Young JR, Ravindran A, Ruan GJ, Dasari S, et al. Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status. JAMA Oncol. 2022;8:1816–20.
This study was funded by the National Key R&D Program of China, Ministry of Science and Technology of the People’s Republic of China (2022YFC2304605), Beijing Natural Science Haidian frontier Foundation (Grant No. L222081 to XXC) and the National High Level Hospital Clinical Research Funding (2022-PUMCH-B-046).
GG served on advisory board for Opna Bio LLC.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
InformeInformed consent was obtained from all patients included in thed consent was obtained from all patients included in the study.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Chang, L., Qiao, B., Cai, H. et al. Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia 37, 2297–2300 (2023). https://doi.org/10.1038/s41375-023-02032-6